Cartesian Therapeutics (RNAC) Current Deferred Revenue (2015 - 2024)

Cartesian Therapeutics (RNAC) has reported Current Deferred Revenue for 10 consecutive years, with $412000.0 the latest figure, recorded in Q1 2024.

• In Q1 2024, Current Deferred Revenue fell 90.26% year-over-year to $412000.0; the TTM figure through Mar 2024 stood at $412000.0 (down 90.26% YoY), while the FY2023 annual figure was $2.3 million, up 289.71% from the prior year.
• Current Deferred Revenue declined to $412000.0 in Q1 2024 per RNAC's latest filing, from $2.3 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $115.8 million in Q3 2020 and bottomed at $412000.0 in Q1 2024.
• Historically, Current Deferred Revenue has averaged $34.4 million across 5 years, with a median of $9.2 million in 2021.
• Annual changes were most pronounced in 2020 — Current Deferred Revenue soared 11223.46% — and 2022, when it sank 93.55%.
• Cartesian Therapeutics' Current Deferred Revenue stood at $110.8 million in 2020, then sank by 91.7% to $9.2 million in 2021, then tumbled by 93.55% to $593000.0 in 2022, then jumped by 289.71% to $2.3 million in 2023, then plunged by 82.17% to $412000.0 in 2024.
• Business Quant data shows RNAC's Current Deferred Revenue at $412000.0 in Q1 2024, $2.3 million in Q4 2023, and $4.1 million in Q3 2023.